Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Bottom Line: Scientist's Holy Grail

Monday 17 January 1994 19:02 EST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

TO LISTEN to Chris Evans, the fast-talking young scientist behind Chiroscience, you would believe his company has discovered the Holy Grail of drug research - technology that offers the enormous rewards of successful drug discovery but whose wide application reduces the risks.

The fashionably dressed and entrepreneurial Dr Evans seems a million miles away from the traditional image of a scientist. He was also the founder of Celsis International, the biotechnology company that came to the market last July.

He is once again backed by an impressive team that includes Nowell Stebbing, a biotechnology pioneer with Genentech and Amgen in the US who then spent six years as general manager of research at ICI Pharmaceuticals, and John Padfield, the Glaxo manufacturing boss who will join Chiroscience as chief executive.

If the reality of Chiroscience is half as good as Dr Evans makes it sound, investors should make a purchase when the company floats next month.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in